SEC Comment Letter 0000000000-24-004575 to FATE THERAPEUTICS INC (FATE) (CIK 0001434316) (FATE)
FATE THERAPEUTICS INC (FATE) (CIK 0001434316)
Date: April 24, 2024 · CIK: 0001434316 · Accession: 0000000000-24-004575
AI Filing Summary & Sentiment
File numbers found in text: 333-278792
Letter
United States securities and exchange commission logo April 24, 2024 J. Scott Wolchko Chief Executive Officer Fate Therapeutics, Inc. 12278 Scripps Summit Dr. San Diego, CA 92131 Re:Fate Therapeutics, Inc. Registration Statement on Form S-3 Filed April 18, 2024 File No. 333-278792 Dear J. Scott Wolchko: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Natalie Martirossian
Show Raw Text
United States securities and exchange commission logo
April 24, 2024
J. Scott Wolchko
Chief Executive Officer
Fate Therapeutics, Inc.
12278 Scripps Summit Dr.
San Diego, CA 92131
Re:Fate Therapeutics, Inc.
Registration Statement on Form S-3
Filed April 18, 2024
File No. 333-278792
Dear J. Scott Wolchko:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Natalie Martirossian